NASDAQ:RAREUltragenyx Pharmaceutical Stock Price, Forecast & News

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RARE stock has increased by 51.2% and is now trading at $68.59. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) posted its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.91) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.68) by $0.23. The biopharmaceutical company earned $36.31 million during the quarter, compared to the consensus estimate of $36.74 million. Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The firm's revenue was up 99.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.82) earnings per share. View Ultragenyx Pharmaceutical's earnings history.

13 brokerages have issued 12-month price objectives for Ultragenyx Pharmaceutical's shares. Their forecasts range from $66.00 to $87.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $77.09 in the next year. This suggests a possible upside of 12.4% from the stock's current price. View analysts' price targets for Ultragenyx Pharmaceutical.

Headlines about RARE stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a daily sentiment score of -2.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutUltragenyx Pharmaceutical.

Some companies that are related to Ultragenyx Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Merck KGaA (MKGAF), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Beigene (BGNE), Sarepta Therapeutics (SRPT), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Mylan (MYL), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS) and ACADIA Pharmaceuticals (ACAD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Gilead Sciences (GILD), Exelixis (EXEL), TG Therapeutics (TGTX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH) and Intercept Pharmaceuticals (ICPT).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital Research Global Investors (11.02%), Capital International Investors (10.28%), BlackRock Inc. (7.88%), Federated Hermes Inc. (6.73%), State Street Corp (3.74%) and Alliancebernstein L.P. (2.37%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View institutional ownership trends for Ultragenyx Pharmaceutical.

RARE stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, First Trust Advisors LP, BlackRock Inc., Alliancebernstein L.P., Morgan Stanley, Morgan Stanley, Cinctive Capital Management LP, and AXA. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga. View insider buying and selling activity for Ultragenyx Pharmaceutical.

RARE stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Bank of New York Mellon Corp, Capital Research Global Investors, Fred Alger Management LLC, Capital International Investors, Castleark Management LLC, Geode Capital Management LLC, and Rhenman & Partners Asset Management AB. View insider buying and selling activity for Ultragenyx Pharmaceutical.

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RARE stock can currently be purchased for approximately $68.59.

Ultragenyx Pharmaceutical has a market capitalization of $4.09 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]